Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion

Clin Lung Cancer. 2017 May;18(3):e219-e222. doi: 10.1016/j.cllc.2016.12.006. Epub 2016 Dec 22.

Authors

Justin M Allen¹, Alexa B Schrock², Rachel L Erlich², Vincent A Miller², Philip J Stephens², Jeffrey S Ross², Sai-Hong Ignatius Ou³, Siraj M Ali², Davood Vafai⁴

Affiliations

¹ Foundation Medicine, Inc, Cambridge, MA. Electronic address: jallen@foundationmedicine.com.
² Foundation Medicine, Inc, Cambridge, MA.
³ Department of Medicine, Division of Hematology-Oncology, University of California, Irvine, School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA.
⁴ Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA.

PMID: 28089157
DOI: 10.1016/j.cllc.2016.12.006

No abstract available

Keywords: Acquired resistance; EGFR mutation; FGFR3 fusion; Non–small-cell lung cancer; ctDNA.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / genetics*
Afatinib
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung
Cetuximab / therapeutic use
Circulating Tumor DNA / analysis*
Drug Resistance, Neoplasm / genetics
ErbB Receptors / genetics
Female
Gene Expression Profiling
Genome / genetics
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Microtubule-Associated Proteins / genetics*
Mutation / genetics
Neoplasm Metastasis
Oncogene Proteins, Fusion / genetics*
Quinazolines / therapeutic use
Receptor, Fibroblast Growth Factor, Type 3 / genetics*
Recurrence

Substances

Circulating Tumor DNA
Microtubule-Associated Proteins
Oncogene Proteins, Fusion
Quinazolines
TACC3 protein, human
Afatinib
EGFR protein, human
ErbB Receptors
FGFR3 protein, human
Receptor, Fibroblast Growth Factor, Type 3
Cetuximab